Rapport Therapeutics, Inc. (RAPP) Form 8-K — Oct 30, 2026
Rapport Therapeutics closed a large triple-pronged financing on October 30, 2026, raising approximately $215.7 million net from an underwritten offering of 8,333,334 shares at $21.00 plus 1,190,476 pre-funded warrants, with the underwriters' 1,428,571-share option exercised in full. Concurrently, the company issued $172.5 million of 2.25% convertible senior notes due 2032 (net proceeds ~$166.8 million) with an initial conversion price of $26.775, a 27.50% premium, and sold $30.0 million of stock in a private placement. Morgan Stanley, Leerink and Evercore led all three legs.
Key figures
- Debt Amount
- 172500000
- Cash Position
- 395000000
- Interest Rate
- 2.25
- Maturity Date
- December 1, 2032
- Gross Proceeds
- approximately $215.7 million net from equity offering; $166.8 million net from notes; $30.0 million PIPE
- Offering Price
- 21
- Shares Offered
- 8333334
- Runway
- funded through end of 2029
- Pipe shares
- 1428571
- Greenshoe notes
- $22.5 million
- Greenshoe shares
- 1428571
- Greenshoe exercised
- in full
- Pre funded warrants
- 1,190,476 warrants at $20.999
- Notes conversion price
- 26.775
- Notes conversion premium
- 27.50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.